Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASA trial of adjuvant pegylated liposomal doxorubicin in older women with endocrine-nonresponsive breast cancer
2005-003434-18Phase 3Terminated
- Sponsor
- International Breast Cancer Study Group
- Start
- Mar 2006
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (3 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Breast cancer free interval. Started Mar 2006; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003434-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003434-18.